Lyell Immunopharma Inc. held its annual meeting of stockholders on May 15, 2025. Stockholders approved the election of Catherine Friedman as a Class I director. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. A proposal to effect a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-25, at the discretion of the Board of Directors, was also approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-123970), on May 21, 2025, and is solely responsible for the information contained therein.